Key facts
- Renibus Therapeutics’s last known valuation is $269.0M (Jul 2025).
- It has raised $186.7M across 5 recorded rounds; the latest was Later Stage VC ($110.9M) in May 2023.
- Notable investors include AG Collective Capital, Bios Partners, CKG Management, Cathexis Ventures.
- Renibus Therapeutics has filed 14 Form Ds with the SEC since 2016, most recently Jul 2025 ($110.9M sold to 59 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Renibus Therapeutics
Funding rounds
5 roundsAbout Renibus Therapeutics
Operator of a biotechnology company intended to develop novel pharmacologic therapies. The company develops novel therapeutics for post-operative surgery complications as well as acute and chronic kidney disease and offers advances for the prevention and management of such diseases, enabling the healthcare sector to access novel therapies to treat various types of health problems and transform outcomes in cardiothoracic surgical patients.
- Sector
- Healthcare
- HQ
- Southlake, TX, United States
- Founded
- 2015
- Employees
- 31
- Website
- renibus.com/
- Ownership
- Privately Held (backing)
Renibus Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Renibus Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Renibus Therapeutics in its N-PORT filings yet. We sweep new filings monthly.